Advertisement

Targeted Oncology

, Volume 11, Issue 1, pp 49–58 | Cite as

RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials

  • Jin Liu
  • Zhixin Sheng
  • Yanxia Zhang
  • Guixin LiEmail author
Original Research Article

Abstract

Objective

To determine the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non-small cell lung cancer (NSCLC), we performed this pooled analysis.

Method

Randomized trials of EGFR-TKIs as treatment for advanced NSCLC were included for this meta-analysis. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data. Pooled estimates of treatment efficacy of EGFR-TKIs in the selected patients by EGFR-mutation status were calculated.

Results

Out of 2134 retrieved articles, 30 randomized controlled trials (RCTs) enrolling more than 4053 patients with wild-type EGFR tumors and 1592 patients with mutant EGFR tumors were identified. For EGFR mutant patients, EGFR-TKIs treatment improved progression-free survival (PFS) compared with chemotherapy: the summary HRs were 0.41 (p < 0.00001) for the first-line setting and 0.46 (p = 0.02) for second/third-line setting, respectively. Also, the same superior trend was found with TKIs maintenance over placebo (HR = 0.14, p < 0.00001) and with TKIs combined with chemotherapy over chemotherapy (HR = 0.49, p = .002) in both the first-line and maintenance therapy settings. For EGFR wild-type patients, EGFR-TKIs have fared worse than chemotherapy in the first-line setting (HR = 1.65, p = .03) and in the second/third-line setting (HR = 1.27, p = .005). However, EGFR-TKIs maintenance still produced a reduction of 19 % in the risk of progression over placebo (HR = 0.81, p = .02). Furthermore, EGFR-TKIs added to chemotherapy as first-line treatment resulted in an improvement of PFS over chemotherapy alone in such wild-type EGFR patients (HR = 0.82, p = .03). In overall survival (OS) analysis, only EGFR-TKIs single agent was inferior to chemotherapy in EGFR wild-type patients (HR = 1.13, p = .02). No statistically significant difference in terms of OS was observed in any other subgroup analysis.

Conclusions

For EGFR mutant patients, EGFR-TKIs therapy produced a prominent PFS benefit in all settings. Among EGFR wild-type patients, EGFR-TKIs were inferior to chemotherapy both for first-line treatment and for second/third-line treatment. However, EGFR-TKIs maintenance and addition of EGFR-TKIs to chemotherapy could provide additive benefit over chemotherapy alone in such EGFR wild-type patients.

Keywords

Overall Survival Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Status Factor Receptor Tyrosine Kinase Inhibitor Platinum Doublet Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We are indebted to Yanhua Sun for assistance with data analysis and critiquing the manuscript.

Conflict of Interest Statement

Jin Liu, Zhixin Sheng, Yanxia Zhang and Guixin Li declare no competing financial interests, and did not receive any financial support.

References

  1. 1.
    Park K, Goto K (2006) A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2(3):561–73CrossRefGoogle Scholar
  2. 2.
    Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–42CrossRefPubMedGoogle Scholar
  3. 3.
    Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–46CrossRefPubMedGoogle Scholar
  4. 4.
    Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–8CrossRefPubMedGoogle Scholar
  5. 5.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–39CrossRefPubMedGoogle Scholar
  6. 6.
    Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–500CrossRefPubMedGoogle Scholar
  7. 7.
    Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10(5):432–3CrossRefPubMedGoogle Scholar
  8. 8.
    Ettinger DS, Akerley W, Borghaei H et al (2012) NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. J Natl Compr Cancer Netw 10(10):1236–71Google Scholar
  9. 9.
    Laurie SA, Goss GD (2013) Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 31(8):1061–9CrossRefPubMedGoogle Scholar
  10. 10.
    Zhao N, Zhang XC, Yan HH et al (2014) Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 85(1):66–73CrossRefPubMedGoogle Scholar
  11. 11.
    Lee JK, Hahn S, Kim DW et al (2014) Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 311(14):1430–7CrossRefPubMedGoogle Scholar
  12. 12.
    Bucher HC, Guyatt GH, Griffith LE et al (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–91CrossRefPubMedGoogle Scholar
  13. 13.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–34CrossRefPubMedGoogle Scholar
  14. 14.
    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Han J-Y, Park K, Kim S-W et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122–8CrossRefPubMedGoogle Scholar
  16. 16.
    Mok TS, Wu Y-L, Thongprasert S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–57CrossRefPubMedGoogle Scholar
  17. 17.
    Fukuoka M, Wu Y-L, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–74CrossRefPubMedGoogle Scholar
  18. 18.
    Heigener DF, Deppermann KM, Pawel JV et al (2014) Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer. Lung Cancer 84(1):62–6CrossRefPubMedGoogle Scholar
  19. 19.
    Gridelli C, Ciardiello F, Gallo C et al (2012) First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 30(24):3002–11CrossRefPubMedGoogle Scholar
  20. 20.
    Chen YM, Tsai CM, Fan WC et al (2012) Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 7(2):412–8CrossRefPubMedGoogle Scholar
  21. 21.
    Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–8CrossRefPubMedGoogle Scholar
  22. 22.
    Mitsudomi T, Morita S, Yatabe Y et al (2012) Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 30(15 suppl):7521Google Scholar
  23. 23.
    Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–8CrossRefPubMedGoogle Scholar
  24. 24.
    Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24(1):54–9CrossRefPubMedGoogle Scholar
  25. 25.
    Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–46CrossRefPubMedGoogle Scholar
  26. 26.
    Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–42CrossRefPubMedGoogle Scholar
  27. 27.
    Zhou C, Wu YL, Liu X et al (2012) Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30(15 suppl):7520Google Scholar
  28. 28.
    Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15–32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer. J Clin Oncol 26(26):4244–52CrossRefPubMedGoogle Scholar
  29. 29.
    Douillard J-Y, Shepherd FA, Hirsh V et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28(5):744–52CrossRefPubMedGoogle Scholar
  30. 30.
    Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–18CrossRefPubMedGoogle Scholar
  31. 31.
    Sun JM, Lee KH, Kim SW et al (2012) Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01). Cancer 118(24):6234–42CrossRefPubMedGoogle Scholar
  32. 32.
    Zhou Q, Cheng Y, Yang JJ et al (2014) Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol 25(12):2385–91CrossRefPubMedGoogle Scholar
  33. 33.
    Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14(10):981–8CrossRefPubMedGoogle Scholar
  34. 34.
    Kawaguchi T, Ando M, Asami K et al (2014) Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 32(18):1902–8CrossRefPubMedGoogle Scholar
  35. 35.
    Ciuleanu T, Stelmakh L, Cicenas S et al (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13(3):300–8CrossRefPubMedGoogle Scholar
  36. 36.
    Li N, Ou W, Yang H (2014) A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer 120(9):1379–86CrossRefPubMedGoogle Scholar
  37. 37.
    Karampeazis A, Voutsina A, Souglakos J et al (2013) Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 119(15):2754–64CrossRefPubMedGoogle Scholar
  38. 38.
    Gregorc V, Novello S, Lazzari C (2014) Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 15(7):713–21CrossRefPubMedGoogle Scholar
  39. 39.
    Lee SM, Khan I, Upadhyay S et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13(11):1161–70CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lee SM, Khan I, Upadhyay S et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13(11):1161–70CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–37CrossRefPubMedGoogle Scholar
  42. 42.
    Zhu C-Q, da Cunha SG, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(26):4268–675CrossRefPubMedGoogle Scholar
  43. 43.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 353(2):123–32CrossRefPubMedGoogle Scholar
  44. 44.
    Pérol M, Chouaid C, Pérol D et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30(28):3516–24CrossRefPubMedGoogle Scholar
  45. 45.
    Zhang L, Ma S, Song X et al (2011) Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 13(5):466–75CrossRefGoogle Scholar
  46. 46.
    Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–9CrossRefPubMedGoogle Scholar
  47. 47.
    Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22(5):777–84CrossRefPubMedGoogle Scholar
  48. 48.
    Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081–92CrossRefPubMedGoogle Scholar
  49. 49.
    Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22(5):785–94CrossRefPubMedGoogle Scholar
  50. 50.
    Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12):1545–52CrossRefPubMedGoogle Scholar
  51. 51.
    Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12):1545–52CrossRefPubMedGoogle Scholar
  52. 52.
    Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer. J Clin Oncol 23(25):5892–9CrossRefPubMedGoogle Scholar
  53. 53.
    Johnson BE, Kabbinavar F, Fehrenbacher L et al (2013) ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 31(31):3926–34CrossRefPubMedGoogle Scholar
  54. 54.
    Alimujiang S, Zhang T, Han ZG et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 14(4):2413–9CrossRefPubMedGoogle Scholar
  55. 55.
    Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–66CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–40CrossRefPubMedGoogle Scholar
  57. 57.
    Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27(4):591–8CrossRefPubMedGoogle Scholar
  58. 58.
    Ciardiello F, Caputo R, Bianco R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6(5):2053–63PubMedGoogle Scholar
  59. 59.
    Sirotnak FM, Zakowski MF, Miller VA et al (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6(12):4885–92PubMedGoogle Scholar
  60. 60.
    Lee CK, Brown C, Gralla RJ et al (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105(9):595–605CrossRefPubMedGoogle Scholar
  61. 61.
    Jänne PA, Wang X, Socinski MA et al (2012) Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 30(17):2063–9CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Jin Liu
    • 1
  • Zhixin Sheng
    • 2
  • Yanxia Zhang
    • 3
  • Guixin Li
    • 4
    Email author
  1. 1.Shandong UniversityJinanChina
  2. 2.Department of HematologyWeifang People’s HospitalWeifangChina
  3. 3.Department of OncologyLin Yi People’s HospitalLinyiChina
  4. 4.Department of OncologyWeifang Medical UniversityWeifangChina

Personalised recommendations